Porton Shanghai Pudong Facility Obtained ISO 14001 and ISO 45001 Certification

Porton Pharma Solutions Ltd. (hereinafter "Porton") is glad to announce that its Shanghai Pudong R&D and Manufacturing Site (Shanghai Porton Nova Biologics (WGQ), Ltd.) successfully obtained ISO 14001 Environmental Management System certification and ISO 45001 Occupational Health and Safety Management System certification. This dual certification marks that the base has achieved internationally advanced levels in environmental sustainability management as well as employee health and safety management. It adds another authoritative endorsement to Porton's global production and supply system, further validating the company's commitment to sustainable development. ISO 14001 and ISO 45001 are two core management system standards developed by the International Organization for Standardization (ISO), with the former focusing on environmental protection and efficient resource utilization, and the latter on occupational health and safety risk prevention and control.

The management system audit involved rigorous on-site inspections and reviews of system documentation, thoroughly evaluating the base’s environmental and occupational health and safety management systems. Successfully passing this ISO audit demonstrates the robustness of Porton's quality management system and integrated service capabilities. Guided by the ISO standards, the company has systematically built a comprehensive environmental and occupational health and safety management system. This includes creating a green production cycle covering energy management, waste disposal, and recycling, while simultaneously establishing an organization-wide occupational health and safety management network. Through mechanisms such as risk classification and control, routine hazard investigation and rectification, and regular emergency drills, the company ensures all-around employee safety, enabling it to provide higher-quality CDMO services to global clients.

As a core facility of Porton's biologics and conjugates CDMO segment, there have been over 30 projects delivered in Shanghai Pudong R&D and Manufacturing Site since it's operation in September 2023. Its supporting quality system received EU Qualified Person (QP) certification in June 2025.

Moving forward, Porton will adhere to the "One Porton, One Quality" quality management principle, integrating quality management throughout the entire drug lifecycle. The company will continue to advance its sustainable development strategy, supporting global pharmaceutical companies and biotech firms in their green initiatives by providing high-quality, integrated CDMO services for new molecular entities.